Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004846 · ClinicalTrials.gov registry record
Nucleic Acid Amplification Testing (NAT) of Blood Donors for HCV and HIV
A clinical trial, sponsored by National Institutes of Health Clinical Center (CC).
- Completed
- Registry status
- 30,000
- Enrollment target
NCT00004846: Completed study, sponsored by National Institutes of Health Clinical Center (CC).
NCT00004846 is a clinical trial that has completed, run by National Institutes of Health Clinical Center (CC). The registered enrollment target is 30,000 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004846 has completed, sponsored by National Institutes of Health Clinical Center (CC).
- COMPLETED
- Registry status
- 30,000 participants
- Enrollment target
Study Summary
This study will evaluate the accuracy of an experimental test method called nucleic acid amplification technology (NAT) in detecting human immunodeficiency virus (HIV) and hepatitis C virus (HCV). This test amplifies the nucleic acid in a virus more than a million-fold, allowing early detection of minute quantities of virus in the blood. Blood donors to the National Institutes of Health's Department of Transfusion Medicine (blood bank) will have their blood screened with transcription mediated amplification, a type of NAT test. Donors whose blood is found positive for HIV or HCV by NAT testing will be notified and asked to participate in this study. Those who agree will provide a blood sample about once a week for 3 months. The samples will be tested with additional assays to detect evidence of HIV or HCV infection. If the test results are confirmed positive, no more blood samples will be collected. The results of the tests and their significance will be explained to participants. It is anticipated that NAT screening will reduce the risk of transfusion-related HIV transmission from the current 1 in 650,000 to 1 in a million and the risk of HCV transmission from the current 1 in 100,000 to 1 in 350,000. It is possible that these tests will completely eliminate the risk of transmitting these diseases through blood transfusion.
Interventions
- DRUG ABC/Gen-Probe/Chiron HIV-1/HCV 001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30,000 participants |
| Start Date | 1999-12 |
| Est. Completion | 2002-10 |
What the finished NCT00004846 record still lists
NCT00004846 is an observational study that tracks outcomes without assigning an intervention. Its 30,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which ABC/Gen-Probe/Chiron HIV-1/HCV 001 is the first listed.
NCT00004846 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00004846 about?
NCT00004846 is a clinical study titled "Nucleic Acid Amplification Testing (NAT) of Blood Donors for HCV and HIV". This study will evaluate the accuracy of an experimental test method called nucleic acid amplification technology (NAT) in detecting human immunodeficiency virus (HIV) and hepatitis C virus (HCV). This test amplifies the nucleic acid in a virus more than a million-fold, allowing early detection of m...
What is the current status of trial NCT00004846?
This trial is currently completed. The enrollment target is 30,000 participants. The study started on 1999-12. Estimated completion is 2002-10.
What interventions are being tested in trial NCT00004846?
The interventions under investigation include: ABC/Gen-Probe/Chiron HIV-1/HCV 001 (DRUG).
Who is sponsoring clinical trial NCT00004846?
This trial is sponsored by National Institutes of Health Clinical Center (CC), which has 338 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00684580 · 30,000 participants
Protocol For Collecting Data On Patients With Childhood Cancer
- NCT03053193 · 30,000 participants
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
- NCT03689595 · 30,000 participants
Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)
- NCT04834869 · 30,000 participants
COVID-19 Vaccines Safety Tracking (CoVaST)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia